Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDANASDAQ:KYTXNASDAQ:RVNCNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$6.90+0.7%$6.57$4.74▼$9.16$396.61M0.9491,181 shs95,880 shsKYTXKyverna Therapeutics$2.65+3.9%$2.14$1.78▼$16.64$114.53M2.17420,098 shs245,802 shsRVNCRevance Therapeutics$3.65$3.65$2.30▼$6.65$381.02M0.93.37 million shsN/AVERVVerve Therapeutics$4.80+7.9%$4.48$2.86▼$9.31$427.89M1.821.90 million shs3.50 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada0.00%+2.87%+2.40%+0.44%+29.41%KYTXKyverna Therapeutics0.00%+11.01%+10.53%-2.70%-79.89%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+28.52%VERVVerve Therapeutics0.00%+1.61%-14.64%-28.20%-14.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKMDAKamada4.1725 of 5 stars3.45.00.00.02.91.73.1KYTXKyverna Therapeutics1.7435 of 5 stars3.61.00.00.02.61.70.0RVNCRevance Therapeutics2.1081 of 5 stars3.10.00.04.70.61.70.6VERVVerve Therapeutics3.7276 of 5 stars4.52.00.00.03.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 2.75Moderate Buy$14.67112.56% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50598.11% UpsideRVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideVERVVerve Therapeutics 3.00Buy$25.75436.46% UpsideCurrent Analyst Ratings BreakdownLatest KYTX, VERV, KMDA, and RVNC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/25/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$167.24M2.37$0.39 per share17.90$4.25 per share1.62KYTXKyverna Therapeutics$7.03M16.29N/AN/AN/A∞RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11VERVVerve Therapeutics$59.61M7.18N/AN/A$7.31 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$8.28M$0.2924.6421.560.979.92%6.30%4.49%8/13/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)VERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)Latest KYTX, VERV, KMDA, and RVNC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamadaN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ALatest KYTX, VERV, KMDA, and RVNC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A4.842.73KYTXKyverna TherapeuticsN/A10.5010.50RVNCRevance TherapeuticsN/A4.123.05VERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%KYTXKyverna Therapeutics18.08%RVNCRevance Therapeutics97.70%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipKMDAKamada36.10%KYTXKyverna Therapeutics22.00%RVNCRevance Therapeutics5.10%VERVVerve Therapeutics19.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.48 million36.73 millionOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableKYTX, VERV, KMDA, and RVNC HeadlinesRecent News About These CompaniesVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 2 at 4:05 PM | globenewswire.comBank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV)June 1 at 3:21 AM | marketbeat.comTwo Sigma Advisers LP Has $1.65 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)May 31 at 3:55 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Two Sigma Investments LPMay 31 at 3:47 AM | marketbeat.comNuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 31 at 3:37 AM | marketbeat.comHeart Disease Could Be a Goner When These New Drugs ArriveMay 29, 2025 | msn.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comExperimental drug promising to bring down bad cholesterol by up to 69% completes early stage trialMay 26, 2025 | theprint.inVerve Therapeutics, Inc. (NASDAQ:VERV) Position Lessened by Rafferty Asset Management LLCMay 25, 2025 | marketbeat.comNorthern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)May 25, 2025 | marketbeat.comWall Street Zen Upgrades Verve Therapeutics (NASDAQ:VERV) to "Hold"May 24, 2025 | marketbeat.comGroundbreaking treatment for bad cholesterol on the horizon? This single-use drug shows some promiseMay 24, 2025 | cnbctv18.comStrokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.May 23, 2025 | msn.comHC Wainwright Has Optimistic Outlook of VERV FY2025 EarningsMay 23, 2025 | marketbeat.comMillennium Management LLC Sells 1,105,050 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 23, 2025 | marketbeat.comFY2025 EPS Estimate for Verve Therapeutics Lifted by AnalystMay 23, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for VERV FY2026 Earnings?May 22, 2025 | marketbeat.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21, 2025 | zacks.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LPMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)May 21, 2025 | marketbeat.comVerve Therapeutics Leads The Charge With 2 Other Promising Penny StocksMay 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, VERV, KMDA, and RVNC Company DescriptionsKamada NASDAQ:KMDA$6.90 +0.05 (+0.73%) Closing price 04:00 PM EasternExtended Trading$6.88 -0.02 (-0.29%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Kyverna Therapeutics NASDAQ:KYTX$2.65 +0.10 (+3.92%) Closing price 04:00 PM EasternExtended Trading$2.65 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Revance Therapeutics NASDAQ:RVNC$3.65 0.00 (0.00%) As of 02/6/2025Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Verve Therapeutics NASDAQ:VERV$4.80 +0.35 (+7.87%) Closing price 04:00 PM EasternExtended Trading$4.78 -0.02 (-0.42%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
